• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    E-Vapor Company RLX Technology's Strategic Move: Extends Share Buyback Program Through 2025

    12/29/23 7:25:49 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    China-based e-vapor company RLX Technology Inc (NYSE:RLX) shares are trading higher after it disclosed the extension of its existing share repurchase program.

    The company established the program in December 2021, which will be extended for an additional 24 months through December 31, 2025. 

    Under the existing share repurchase program, the company can repurchase up to $500 million in ordinary shares represented by ADSs till December 31, 2023. 

    As of December 28, 2023, the company had repurchased around $193.5 million of its ordinary shares represented by ADSs.

    The company expects to fund the repurchases out of its existing cash balance.

    As of September 30, 2023, RLX had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, long-term bank deposits, and net and long-term investment securities, of $2.074 billion.

    Earlier this month, RLX entered into two share purchase agreements with two target companies and their respective shareholders for about $25 million to boost international expansion.

    Price Action: RLX shares are up 2.08% at $1.96 premarket on the last check Friday.

    Get the next $RLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    12/31/25 6:03:48 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    11/14/25 6:02:26 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    8/22/25 7:09:03 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RLX Technology Extends US$500 Million Share Repurchase Program

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary share

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care